Prenatal application of magnesium sulfate is recommended to protect fetal neural development and reduce cerebral palsy and the severity of cerebral palsy.The use of magnesium sulfate for fetal neuroprotection is recommended for pregnancies with high risk of preterm delivery within 24 hours，including premature rupture of membranes before full term，premature delivery with intact membranes，and planned preterm delivery due to fetal or maternal indications.Magnesium sulfate therapy should be started within 24 hours before delivery. Magnesium sulfate was infused intravenously within 20-30 min after initial loading of 4 g and maintained at 1 g/h until delivery or 24h.Repeated use of magnesium sulfate is not recommended currently because of limited data on the benefit of retreatment for unborn pregnancies after the initial course of treatment.If delivery is expected before 32 weeks of gestation，the use of magnesium sulfate reduces the severity and risk of cerebral palsy in surviving infants，regardless of the number of fetuses.If FGR is delivered at ＜ 32 weeks of gestation，magnesium sulfate should be used to protect the nerves of the fetus and newborn.